Because of population aging, neurodegenerative diseases become one of the major causes of death. Alzheimer’s disease is the most common neurodegenrative disorder. In the USA in 2013, Alzheimer’s disease was the sixth leading cause of death; 1 of 3 senior was suffering from this disease at his death. Alzheimer’s disease affects more than 10% of Americans over the age of 65.
Parkinson’s disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease. The estimated number of new cases occurring annually (incidence rate) varies according to the studies, but as for Alzheimer’s disease, PD has an incidence rate that increases with age. Worldwide, the number of patients with PD is estimated to be nearly 4.6 million. They will be 9.3 million in 2030, aged 50 years and older.
Nevertheless, few therapies exist and efforts need to be continued to find new drugs for these pathologies.
HCS Pharma wants to develop more relevant assays than those that already exist, by using high content screening technology:
|Parkinson’s disease (PD) is the second most common neurodegenerative disease after Alzheimer’s. PD is a complex heterogeneous disease characterized by the progressive degeneration of dopaminergic neurons in substantia nigra pars compacta. Etiology of sporadic PD, which accounts for >90% of the incidence of the disease, remains unclear. Many lines of evidence have indicated an environmental exposure basis for the disease.|
|Alzheimer||It is becoming increasingly clear that Alzheimer Disease (AD) represents a syndrome with well-defined clinical and neuropathological hallmarks but despite extensive investigation, the causes and mechanisms underlying the initiation and development still remain poorly understood.|